Zikani Therapeutics is a biotechnology startup that is revolutionizing antibiotic treatment. Founded in 2014 and based in Newton, Massachusetts, the company is dedicated to addressing the challenge of resilient gram-negative bacteria. While Zikani has a strong track record in producing safe and effective antibiotics, its focus is now on developing advanced oral and intravenous options to combat critical infections caused by gram-negative bacteria.
The company's flagship antibiotic, azithromycin, has been one of the most widely used globally for years. However, existing macrolides, including azithromycin, have limitations in effectively targeting gram-negative bacteria, which are the primary culprits behind serious infections in the US.
Zikani Therapeutics aims to bridge this gap by pioneering the next generation of macrolides that demonstrate enhanced efficacy against gram-negative bacteria. This is a promising development, considering that previous generations of macrolides have shown minimal effectiveness against these resilient bacteria. The company's commitment to providing both intravenous and oral forms of their antibiotics sets them apart in the industry.
The recent Series A investment of $7.50M on 20th April 2020 underscores investor confidence in Zikani's innovative approach. Notably, the investment was led by Advent Life Sciences and Roche Venture Fund, highlighting the strong support from reputable players in the investment community.
With its unwavering focus on developing solutions for critical infections, Zikani stands at the forefront of the biotechnology, life sciences, and pharmaceutical industries, promising a new era in antibiotic treatment.
